ArticleBMC health services research2026
The costs and benefits of an early access scheme for oncology medicines in Ireland.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccess to new oncology medicines is subject to delays in many countries due to lengthy appraisal processes. This study examines the cost to the Irish healthcare system of implementing a cost-sharing agreement to expedite access to oncology medicines.
methodsThe hypothetical cost of implementing an early access scheme in Ireland was estimated for oncology medicines commencing appraisal in 2022. The scheme would have required the manufacturer to cover the cost for the first 180-day period and provide a further rebate if costs per patient over the whole duration of access exceeded those that would have arisen from the finally agreed price. Costs of the new medicine and savings arising from any therapies displaced were estimated on a daily basis using data published in the technical summaries of the National Centre for Pharmacoeconomics, Ireland (NCPE) assessment for each medicine.
resultsThe scheme would have reduced the time patients waited to access oncology medicines by more than two years on average. Assuming new medicines attract a discount of 30% at reimbursement and that medicines with an existing agreement are subject to a 30% discount, and that a further discount of 10% would be negotiated at reimbursement for the new indication, the costs to the government over the duration of the scheme would have been €64·0 m. Earlier access would have generated an additional 1,590 quality-adjusted life years (QALY) over the lifetime of patients accessing the scheme, after discounting. Costs were sensitive to assumptions on discounts negotiated at reimbursement. Costs fell substantially if patients with private insurance were assumed to access care through that insurance.
conclusionProtracted assessment times lead to substantial health losses to patients with cancer in Ireland. A cost-sharing scheme would accelerate access to new treatments by more than two years with costs of €64 m or less in the majority of scenarios considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.